In patients with metastatic breast cancer, immune cells from a genetically matched donor can attack and shrink tumors, researchers from the National Cancer Institute (NCI) announced today at the Annual Meeting of the American Society of Clinical Oncology in Chicago. This is the first time researchers have clearly demonstrated this type of immune response, known as a graft-versus-tumor effect, acting against breast cancer.
"Graft-versus-tumor effects have been shown to be useful in treating cancers of the blood, such as leukemia and lymphoma. Breast cancer, however, has generally been resistant to immune-based therapies," said Michael Bishop, M.D., of NCIs Center for Cancer Research, the lead author on the study. "Although the tumors of patients in this study were not completely eliminated by the treatment, the responses we saw provide hope that immunotherapies for breast cancer are worth pursuing."
Tumor regression has been observed in the past in some patients with metastatic breast cancer who received stem cell transplants, but it was unclear whether immune cells had attacked the tumor or the tumor was shrinking in response to chemotherapy drugs administered prior to the transplant. The design of this clinical trial, however, allowed researchers to attribute tumor regression to a true graft-versus-tumor effect.
Each of the 13 patients in the Phase I trial had received multiple previous treatments for metastatic breast cancer. In the study, patients first received conventional doses of chemotherapy to kill cancer cells and reduce the cells in their immune system so that donor cells could replace them. They then received stem cells from the blood of HLA-matched siblings. HLA-matched donor cells, which have the same set of proteins (known as human leukocyte-associated antigens) on their surface as the patients own cells, are much more likely to be accepted by the patients body.
NCI Press Office | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
19.03.2018 | Physics and Astronomy
19.03.2018 | Materials Sciences
19.03.2018 | Event News